Caribou Biosciences, Inc. expected to post a loss of 32 cents a share - Earnings Preview
Caribou Biosciences, Inc. <CRBU.OQ> expected to post a loss of 32 cents a share - Earnings Preview
Caribou Biosciences, Inc. CRBU.OQ CRBU.O is expected to show a fall in quarterly revenue when it reports results on August 13 (estimated) for the period ending June 30 2026
The Berkeley California-based company is expected to report a 14.5% decrease in revenue to $2.279 million from $2.67 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Caribou Biosciences, Inc. is for a loss of 32 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Caribou Biosciences, Inc. is $10.50, about 532.5% above its last closing price of $1.66
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.31 | -0.32 | -0.26 | Beat | 18.2 |
Dec. 31 2026 | -0.31 | -0.31 | -0.28 | Beat | 9.7 |
Sep. 30 2025 | -0.35 | -0.36 | -0.30 | Beat | 16.7 |
Jun. 30 2025 | -0.41 | -0.39 | -0.58 | Missed | -48 |
Mar. 31 2025 | -0.45 | -0.44 | -0.43 | Beat | 2.8 |
Dec. 31 2024 | -0.42 | -0.42 | -0.39 | Beat | 7.2 |
Sep. 30 2024 | -0.47 | -0.45 | -0.38 | Beat | 15.5 |
Jun. 30 2024 | -0.46 | -0.46 | -0.42 | Beat | 8.3 |
This summary was machine generated August 11 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)